Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT

NCT05976230 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05976230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05976230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
September 4, 2023
Completion date
May 29, 2025
Enrollment
1,125 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension